Home / Intelligence / Blog / Kaiser Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral
Published February 19, 2021
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam
ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez, MD, MS, MBA, all experts in the field of Digital Therapeutics (DTx), about the […]
Payer Predictions: Evolution of the U.S. Digital Therapeutics Reimbursement Landscape
Available On Demand
The digital therapeutics (DTx) market is growing rapidly, but a lack of clarity around their reimbursement framework in the U.S. means that there is limited coverage. DTx developers— and pharmaceutical organizations seeking an integrated digital offering— are left to wonder how the payer landscape will evolve as they strategize for the future. Join Trinity Life […]
Reimbursement of Digital Therapeutics in the U.S.
Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans. Coverage of […]